Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.34 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.34 |
| ▸ | NCF1 | P14598 | 1/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.31 |
| ▸ | GNAI3 | P08754 | 3/20 | 0.30 |
| ▸ | GNAO1 | P09471 | 3/20 | 0.30 |
| ▸ | GNAI1 | P63096 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18967092 | 1.00 | MBTD1 (0.34) | MBTD1L3MBTL3NCF1HRH4GNAI3 | |
| SCHEMBL15338322 | 1.00 | MBTD1 (0.34) | MBTD1L3MBTL3NCF1HRH4GNAI3 | |
| SCHEMBL12560847 | 1.00 | MBTD1 (0.34) | MBTD1L3MBTL3NCF1HRH4GNAI3 | |
| SCHEMBL23866134 | 1.00 | MBTD1 (0.34) | MBTD1L3MBTL3NCF1HRH4GNAI3 | |
| Hydrochloric Acid SCHEMBL30938586 | 0.98 | MBTD1 (0.33) | MBTD1L3MBTL3NCF1HRH4GNAI3 | |
| Hydrochloric Acid SCHEMBL31430092 | 0.98 | MBTD1 (0.33) | MBTD1L3MBTL3NCF1HRH4GNAI3 | |
| SCHEMBL19343102 | 0.88 | MBTD1 (0.33) | MBTD1L3MBTL3HRH4 | |
| SCHEMBL10381139 | 0.88 | HRH4 (0.40) | MBTD1L3MBTL3NCF1HRH4 | |
| SCHEMBL12605050 | 0.87 | MBTD1 (0.34) | MBTD1L3MBTL3NCF1GNAI3GNAO1 | |
| SCHEMBL4406747 | 0.87 | MBTD1 (0.34) | MBTD1L3MBTL3NCF1GNAI3GNAO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4611743-A1 | TRIAZINES USEFUL AS INHIBITORS OF NOD-LIKE RECEPTOR PROTEIN 3 | Merck Sharp & Dohme LLC (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-4590672-A1 | PHTHALAZINE DERIVATIVES USEFUL AS INHIBITORS OF NOD-LIKE RECEPTOR PROTEIN 3 | Merck Sharp & Dohme LLC (US) | 2025-07-30 | — | — | EP | disclosed |
| CN-119907797-A | Phthalazine derivatives as NOD-like receptor protein 3 inhibitors | 默沙东有限责任公司 | 2025-04-29 | — | — | CN | disclosed |
| WO-2024097598-A1 | TRIAZINES USEFUL AS INHIBITORS OF NOD-LIKE RECEPTOR PROTEIN 3 | MERCK SHARP & DOHME LLC (US) | 2024-05-10 | — | — | WO | disclosed |
| WO-2024097598-A1 | TRIAZINES USEFUL AS INHIBITORS OF NOD-LIKE RECEPTOR PROTEIN 3 | MERCK SHARP & DOHME LLC (US) | 2024-05-10 | — | — | WO | disclosed |
| US-20240124451-A1 | PHTHALAZINE DERIVATIVES USEFUL AS INHIBITORS OF NOD-LIKE RECEPTOR PROTEIN 3 | MERCK SHARP & DOHME LLC (US) | 2024-04-18 | — | — | US | disclosed |
| WO-2024064245-A1 | PHTHALAZINE DERIVATIVES USEFUL AS INHIBITORS OF NOD-LIKE RECEPTOR PROTEIN 3 | MERCK SHARP & DOHME LLC (US) | 2024-03-28 | — | — | WO | disclosed |
| WO-2024064245-A1 | PHTHALAZINE DERIVATIVES USEFUL AS INHIBITORS OF NOD-LIKE RECEPTOR PROTEIN 3 | MERCK SHARP & DOHME LLC (US) | 2024-03-28 | — | — | WO | disclosed |
| WO-2021222353-A1 | MACROCYCLIC INHIBITORS OF PEPTIDYLARGININE DEIMINASES | GILEAD SCIENCES, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| EP-3885342-A1 | BICYCLIC INHIBITORS OF PAD4 | Padlock Therapeutics, Inc. (US) | 2021-09-29 | — | — | EP | disclosed |
| EP-3386505-B1 | AZA-BENZIMIDAZOLE INHIBITORS OF PAD4 | PADLOCK THERAPEUTICS INC (US) | 2020-09-23 | — | — | EP | disclosed |
| US-9963448-B2 | Bicyclic inhibitors of PAD4 | PADLOCK THERAPEUTICS, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-9765093-B2 | Aza-benzimidazole inhibitors of PAD4 | PADLOCK THERAPEUTICS, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| WO-2017147102-A1 | HETEROARYL INHIBITORS OF PAD4 | PADLOCK THERAPEUTICS, INC. (US) | 2017-08-31 | — | — | WO | disclosed |
| WO-2017100601-A1 | AZA-BENZIMIDAZOLE INHIBITORS OF PAD4 | PADLOCK THERAPEUTICS, INC. (US) | 2017-06-15 | — | — | WO | disclosed |
| WO-2017100594-A1 | BICYCLIC INHIBITORS OF PAD4 | PADLOCK THERAPEUTICS, INC. (US) | 2017-06-15 | — | — | WO | disclosed |
| US-20170166592-A1 | AZA-BENZIMIDAZOLE INHIBITORS OF PAD4 | PADLOCK THERAPEUTICS, INC. | 2017-06-15 | — | — | US | disclosed |
| US-20170166565-A1 | BICYCLIC INHIBITORS OF PAD4 | PADLOCK THERAPEUTICS, INC. | 2017-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124451-A1 | PHTHALAZINE DERIVATIVES USEFUL AS INHIBITORS OF NOD-LIKE RECEPTOR PROTEIN 3 | NLRP3, FABP3, NOD2 | MBTD1 2510/4885L3MBTL3 1658/4885NCF1 150/4885 |
| US-20170166565-A1 | BICYCLIC INHIBITORS OF PAD4 | PADI4, PADI1, PADI2 | MBTD1 1314/4885L3MBTL3 1631/4885NCF1 1076/4885 |
| US-20170166592-A1 | AZA-BENZIMIDAZOLE INHIBITORS OF PAD4 | PADI4, PADI1, PADI6 | MBTD1 532/4885L3MBTL3 1934/4885NCF1 1234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.